Charles Schwab
DNA icon

Charles Schwab’s Ginkgo Bioworks DNA Stock Holding History

Charles Schwab’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.91M Buy
394,607
+62,213
+19% +$520K ﹤0.01% 2570
2026
Q1 		$2.04M Sell
332,394
-25,901
-7% -$215K ﹤0.01% 2716
2025
Q4 		$2.98M Buy
358,295
+14,737
+4% +$159K ﹤0.01% 2638
2025
Q3 		$5.01M Buy
343,558
+12,019
+4% +$144K ﹤0.01% 2444
2025
Q2 		$3.73M Buy
331,539
+98,389
+42% +$762K ﹤0.01% 2457
2025
Q1 		$1.33M Sell
233,150
-567
-0.2% -$5.78K ﹤0.01% 2743
2024
Q4 		$2.3M Buy
233,717
+17,372
+8% +$149K ﹤0.01% 2633
2024
Q3 		$1.76M Buy
216,345
+49,210
+29% +$493K ﹤0.01% 2746
2024
Q2 		$2.23M Sell
167,135
-30,179
-15% -$900K ﹤0.01% 2677
2024
Q1 		$9.16M Buy
197,314
+5,781
+3% +$299K ﹤0.01% 2029
2023
Q4 		$12.9M Buy
191,533
+6,073
+3% +$372K ﹤0.01% 1857
2023
Q3 		$13.4M Buy
185,460
+38,852
+27% +$3.11M ﹤0.01% 1753
2023
Q2 		$10.9M Buy
146,608
+12,862
+10% +$761K ﹤0.01% 1876
2023
Q1 		$7.12M Buy
133,746
+15,638
+13% +$991K ﹤0.01% 2039
2022
Q4 		$7.98M Buy
118,108
+18,090
+18% +$1.66M ﹤0.01% 1981
2022
Q3 		$12.5M Buy
100,018
+34,851
+53% +$4.15M ﹤0.01% 1690
2022
Q2 		$6.2M Sell
65,167
-9,812
-13% -$1.2M ﹤0.01% 2096
2022
Q1 		$12.1M Buy
74,979
+712
+1% +$139K ﹤0.01% 1839
2021
Q4 		$24.7M Buy
+74,267
New +$35.3M 0.01% 1409

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Charles Schwab's DNA Position: Q2 2026 in Review

Charles Schwab increased its Ginkgo Bioworks (DNA) stake by 19% in Q2 2026, buying an estimated $520K and bringing the position to 394,607 shares worth $3.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2570.

Charles Schwab first reported a position in DNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $24.7M in Q4 2021. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Charles Schwab held 394,607 shares of Ginkgo Bioworks worth $3.91M as of Q2 2026.
  • Charles Schwab bought 62,213 Ginkgo Bioworks shares in Q2 2026, an estimated $520K.
  • Ginkgo Bioworks made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2570 holding.
  • Charles Schwab first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 19 quarters since.
  • Charles Schwab's Ginkgo Bioworks position peaked at $24.7M in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.